Ema has assessed that a booster of the Pfizer vaccine (Comirnaty) contributes to increased antibody production in people aged 18 to 55 when given at least six months after the second dose.
This was explained in a note released today by the European Medicines Agency.
In the press release, the EMA underlines the importance of distinguishing, in the evaluation of the third dose, between people who have important forms of immunodeficiencies and those who instead have an ordinary functioning of the immune system.
For the latter, in practice, the Agency gives the green light to the third dose of Comirnaty to over 18s six months after the second dose, while it states that Moderna's vaccine, Spikevax, is still under observation.
National health authorities can then adopt recommendations on the use of boosters taking into account the data acquired so far.
"The risk of heart inflammation or other very rare effects after a recall is not known - reads the note - and is carefully monitored. As with all other drugs, the EMA will continue to collect and evaluate all safety and health data. efficacy of vaccines ".
As for the implementation of vaccination campaigns in the various EU countries, the Agency observes that "they remain a prerogative" of the competent national authorities ".
These organisms are the ones that best "can assess local conditions, including the spread of the virus and its variants, the availability of vaccines and the capabilities of the national health system".
(Unioneonline / F)
